News

2020.12.30, Taipei, 

Taiwan PharmaEssentia (6446) published the first English version of its ‘Sustainability Report 2019' as part of its commitment to promote sustainability as a core corporate value, disclose ESG information, fulfill the company’s purpose of establishment and adhere to the principles of ‘Access to Medicine’ by ensuring that patients can get the medicines to address their medical needs.

 In 2019, Ropeginterferon alfa-2b (Besremi TM), which was invented by PharmaEssentia (6446), successfully obtained the first EMA marketing authorization approval. At the same time that our company goes to global markets, we began to plan our first year of corporate sustainability and set the “Year of Review and Planning” as our first-year goal.  By referring to the GRI Standards issued by the Global Reporting Initiative (GRI) and keeping in line with other international reporting standards, the principles of information disclosure in this sustainability report were strengthened. The company disclosed its ESG (Environmental (E), Society (S) and Governance (G)), three non-financial aspects of information, to provide key stakeholders with more useful decision-making information about its sustainable management performance and commitments. Today, the company published the first English version of its Sustainability Report 2019, which is also expected to provide another channel for the company to communicate with all stakeholders.   

The "2019 Sustainability Report" specifically focused on the topic of "Access to Medicine", which is the company’s core concept, as we aim to improve "accessibility", "affordability" and "availability" of our medicine products. The company follows the framework of the Access to Medicine Index 2018 to formulate its strategies and guidelines to reduce the gap between patients’ Access to Medicines and allow patients to obtain them in a reasonable, affordable, suitable and easy way to meet their demands timely. This mission and responsibility can also be echoed and linked with the Goal 3 in the Sustainable Development Goals (SDGs) introduced by the United Nations in 2015. It occupies an important part of the right to health in our international health systems and human rights. The company’s original intention and purpose is to solve the problem of patients suffering and promote the health and well-being of all mankind through successful new drug products development. "Access to Medicine" is crucial to maintain human public health by providing patients with reasonable and affordable drugs, including with a stable source of supply to obtain the drugs that patients need and to protect their right to use drugs.  

 In the first year of corporate sustainability, the company has set up an “ Executive Center for Corporate Sustainability (ECCS)” by using the common language of global sustainable development as described in the United Nations’ 17 SDGs, and to align the company’s business strategic directions with international sustainability trends.   

Environment: 

 In response to the problem of global warming, the Company is committed to reduce the public health risks caused by global warming. 

              In 2019, we have evaluated and started the plan to introduce the "ISO 14064-1: 2018 Greenhouse Gas Inventory management", and it is 

                expected to be implemented in September 2020. Through the inventory management of greenhouse gas emission data, the company has 

               set the targets of its carbon reduction plan. 

              In addition, the disposal of waste and the operation of hazardous chemicals due to the company's business are also managed by strict 

                procedures.   

Society: 

Considering the characteristics of the biotechnology/biopharmaceutical industry, we are committed to talent development, product quality and

 patient safety as follows: 

 Building a friendly, diverse, inclusive and safe workplace environment.

 The number and ratio of male and female employees who were employed at the end of 2019 was significantly equal.

 In terms of senior executives, women accounted for about 30%, and local Taiwanese talents accounted for 97%.

 Ensuring to provide the safety and effectiveness of the drugs to countries around the world, the company has also set up a drug

       safety monitoring team and developed a global drug safety notification system.

 In a more complex medical environment, we adhere to "Access to Medicine" to determine the patient's needs for treatment.

Focusing on research and cooperation to develop new drugs to provide patients with the best treatment options.

 Setting reasonable drug prices that are responsible to the society based on multiple measurement standards.

 Establish a reliable drug supply mechanism and patient assistance plan.   

 Corporate Governance:

 The company was included in the "top 6%-20%" range in the 2019 Corporate Governance Evaluation Results of TWSE/TPEx 

     Listed Companies.  

 In 2020, we formally set up an “ Executive Center of Corporate Sustainability (ECCS)” under the Board of Directors and the CEO 

    to  continue to implement the company’s management measures on corporate sustainability issues. The Center is aiming to

    promote corporate sustainability to meet the requirements of our stakeholders, and to create sustainable value for the company. 

 In the Sustainability Report 2019, the company  identified 11 types of key stakeholders along the company whole value chain and its business model. From the three non-financial (sustainability) aspects of environment, society, and governance, through a solid and complete systematic analysis, the company has also identified 6 sustainability themes, and 34 sustainability topics. These topics are valued by each of our stakeholders in our operations and are in line with the reporting principles for defining report content and quality by international sustainability reporting standards such as the GRI Standards.  This information is expected to be able to promote a more comprehensive and effective communication with multiple type of stakeholders, and we hope to continue to develop short, medium and long-term sustainability goals, and continue to track and improve the management performance in order to create long-term value for the company and all stakeholders.

Relevant information can also be obtained as follows: 

            PharmaEssentia Corp. website: https://pharmaessentia-tpe.com/tw/news_latest

 IPO company’s Public Information Observation Station: https://mops.twse.com.tw/mops/web/t100sb11

 PharmaEssentia’s Executive Center of Corporate Sustainability, 

 Phone:+886.2 26557688 

E-mail: CSR-ESG@pharmaessentia.com